Cerebral Amyloid Angiopathy and the Fibrinolytic System: Is Plasmin a Therapeutic Target?. Issue 8 (15th June 2021)

• Record Type: Journal Article
• Authors: Mutimer, Chloe A.; Keragala, Charithani B.; Markus, Hugh S.; Werring, David J.; Cloud, Geoffrey C.; Medcalf, Robert L.
• Is Part Of: Stroke. Volume 52:Issue 8(2021)
• Page Start: 2707
• Page End: 2714
• Publication Date: 2021-06-15
• Subjects: cerebral amyloid angiopathy -- cerebral hemorrhage -- fibrinolysis -- thrombolytic therapy -- tranexamic acid; Cerebrovascular disease -- Periodicals; Cerebral circulation -- Periodicals; 616.81
• DOI: 10.1161/STROKEAHA.120.033107
• Languages: English
• ISSNs: 0039-2499

Abstract

Abstract : Cerebral amyloid angiopathy is a devastating cause of intracerebral hemorrhage for which there is no specific secondary stroke prevention treatment. Here we review the current literature regarding cerebral amyloid angiopathy pathophysiology and treatment, as well as what is known of the fibrinolytic pathway and its interaction with amyloid. We postulate that tranexamic acid is a potential secondary stroke prevention treatment agent in sporadic cerebral amyloid angiopathy, although further research is required.